Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
Mayo Clinic
University of Kentucky
BeiGene
NanOlogy, LLC
Bristol-Myers Squibb
EpicentRx, Inc.
Samsung Bioepis Co., Ltd.
Humanetics Corporation
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Rutgers, The State University of New Jersey
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Fox Chase Cancer Center
University of Pittsburgh
Eli Lilly and Company
Duke University
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Incyte Corporation
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb
Radiation Therapy Oncology Group
Roswell Park Cancer Institute
University of Alabama at Birmingham
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Rutgers, The State University of New Jersey
H. Lee Moffitt Cancer Center and Research Institute
Swedish Orphan Biovitrum
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Amgen
Memorial Sloan Kettering Cancer Center
New Mexico Cancer Research Alliance